Drug
Tocilizumab 20 Mg/mL Intravenous Solution
Tocilizumab 20 Mg/mL Intravenous Solution is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Active, not recruiting1
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
active_not_recruiting133%
unknown133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_2
Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy
NCT04554771
unknownphase_2
Tocilizumab in Active Moderate-severe Graves' Orbitopathy
NCT04876534
completedphase_2
IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest
NCT03863015
Clinical Trials (3)
Showing 3 of 3 trials
NCT04554771Phase 2
Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy
NCT04876534Phase 2
Tocilizumab in Active Moderate-severe Graves' Orbitopathy
NCT03863015Phase 2
IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3